Association of diet alone, insulin, sulfonylureas, metformin, and thiazolidinediones with the severity of coronary artery disease in patients with diabetes mellitus

American Journal of Therapeutics

Volumn 13, Issue 5, 2006, Pages 400-403

  Ravipati, Gautham ^a   Aronow, Wilbert S ^a   Ahn, Chul ^b   Sujata, Kumbar ^a   Saulle, Leonardo N ^a   Channamsetty, Venu ^a   Weiss, Melvin B ^a  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

Author keywords

Coronary artery disease; Diabetes mellitus; Diet; Insulin; Metformin; Sulfonylureas; Thiazolidinediones

Indexed keywords

2,4 THIAZOLIDINEDIONE DERIVATIVE; INSULIN; METFORMIN; PIOGLITAZONE; ROSIGLITAZONE; SULFONYLUREA DERIVATIVE; TOLBUTAMIDE;

ADULT; ANGIOCARDIOGRAPHY; ARTICLE; COCHRAN ARMITAGE TREND TEST; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIET; DISEASE SEVERITY; DRUG MECHANISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; THORAX PAIN; TREND STUDY;

AGED; CHEST PAIN; CORONARY ANGIOGRAPHY; CORONARY ARTERIOSCLEROSIS; DIABETES MELLITUS; DIET; FEMALE; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MALE; METFORMIN; MIDDLE AGED; SULFONYLUREA COMPOUNDS; THIAZOLIDINEDIONES;

EID: 33748943490     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.mjt.0000208276.65249.1b     Document Type: Article

References (27)

1. Panunti B, Kunhiraman B, Fonseca V. The impact of antidiabetic therapies on cardiovascular disease. Curr Atheroscler Rep. 2005;7:50-57.
2. Spallarossa P, Barsotti A, Cordera R, et al. Reduction of cardiovascular morbidity and mortality in type 2 diabetes: a rational approach to hypoglycemic therapy. J Endocrinol Invest. 2004;27:485-495.
3. Hsueh WA, Law RE. Cardiovascular risk continuum: implications of insulin resistance and diabetes. Am J Med. 1998;105:4S-14S.
4. Choi D, Kim SK, Choi SH, et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care. 2004;27:2654-2660.
5. O'Keefe JH Jr, Miles JM, Harris WH, et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999;74:171-180.
6. UK Prospective Diabetes Study Group. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet. 1998;352:854-865.
7. Langenfeld MR, Forst T, Hohberg C, et al. Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus: results from a controlled randomized study. Circulation. 2005;111:2525-2531.
8. Freed MI, Ratner R, Marcovina SM, et al. Effects of rosiglitazone alone and in combination with atorvastatin on the metabolic abnormalities in type 2 diabetes mellitus. Am J Cardiol. 2002;90:947-952.
9. Lebovitz HE. Rationale for and role of thiazolidinediones in type 2 diabetes mellitus. Am J Cardiol. 2002;90:34G-41G.
10. Kao J, Tobis J, McClelland RL, et al. Relation of metformin treatment to clinical events in diabetic patients undergoing percutaneous intervention. Am J Cardiol. 2004;93:1347-1350.
11. University Group Diabetes Program. A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. V: evaluation of phenformin therapy. Diabetes. 1975;24:65-184.
12. Cleveland JC Jr, Meldrum DR, Cain BS, et al. Oral sulfonylurea hypoglycemic agents prevent ischemic preconditioning in human myocardium. Two paradoxes revisited. Circulation. 1997;96:29-32.
13. Huizar JF, Gonzalez LA, Alderman J, et al. Sulfonylureas attenuate electrocardiographic ST-segment elevation during an acute myocardial infarction in diabetics. J Am Coll Cardiol. 2003;42:1017-1021.
14. Garratt KN, Brady PA, Hassinger NL, et al. Sulfonylurea drugs increase early mortality in patients with diabetes mellitus after direct angioplasty for acute myocardial infarction. J Am Coll Cardiol. 1999;33:119-124.
15. O'Keefe JH, Blackstone EH, Sergeant P, et al. The optimal mode of coronary revascularization for diabetics. Eur Heart J. 1998;19:1696-1703.
16. O'Keefe JH Jr, Miles JM, Harris WH, et al. Improving the adverse cardiovascular prognosis of type 2 diabetes. Mayo Clin Proc. 1999;74:171-180.
17. Aronow WS, Ahn C. Incidence of new coronary events in older persons with diabetes mellitus and prior myocardial infarction treated with sulfonylureas, insulin, metformin, and diet alone. Am J Cardiol. 2001;88:556-557.
18. UK Prospective Diabetes Study Group. Intensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet. 1998;352:837-853.
19. Jollis JG, Simpson RJ Jr, Cascio WE, et al. Relation between sulfonylurea therapy, complications, and outcome for elderly patients with acute myocardial infarction. Am Heart J. 1999;138:S376-S380.
20. Stemmer EA. Diabetes mellitus and vascular disease. In: Aronow WS, Stemmer EA, Wilson SE, eds. Vascular Disease in the Elderly. Armonk: Futura; 1997:199-220.
21. Ness J, Nassimiha D, Feria MI, et al. Diabetes mellitus in older African-Americans, Hispanics, and whites in an academic hospital-based geriatrics practice. Coronary Artery Dis. 1999;10:343-346.
22. Narishige T, Egashira K, Akatsuka Y, et al. Glibenclamide prevents coronary vasodilation induced by β1-adrenoceptor stimulation in dogs. Am J Physiol. 1994;266:H84-H92.
23. ATP blockade in type II diabetes and preconditioning in cardiovascular disease: time for reconsideration. Circulation. 1996;94:2297-2301.
24. + channel blocker. Circulation. 1994;90:700-705.
25. Brady PA, Terzic A. The sulfonylurea controversy: more questions from the heart. J Am Coll Cardiol. 1998;31:950-956.
26. Khawaja U, Campeau R, Tenaglia A, et al. Prevention of ischemic preconditioning in diabetic patients with CAD treated with sulfonylureas [abstract]. J Am Coll Cardiol. 2000;35:339A.
27. Charbonnel B, Dormandy J, Erdmann E, et al. The prospective pioglitazone clinical trial in macrovascular events (PROactive): can pioglitazone reduce cardiovascular events in diabetics? Study design and baseline characteristics of 5238 patients. Diabetes Care. 2004;27:1647-1653.